350 related articles for article (PubMed ID: 28077085)
1. Erythropoiesis stimulating agents and reno-protection: a meta-analysis.
Elliott S; Tomita D; Endre Z
BMC Nephrol; 2017 Jan; 18(1):14. PubMed ID: 28077085
[TBL] [Abstract][Full Text] [Related]
2. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
3. Protocol of a randomized controlled trial of an erythropoietin stimulating agent decision aid for anemia treatment in kidney disease.
Beach LB; Wild M; Ramachandran G; Ikizler HO; Cavanaugh KL
BMC Nephrol; 2016 Jul; 17(1):86. PubMed ID: 27430294
[TBL] [Abstract][Full Text] [Related]
4. Erythropoiesis-stimulating agent slows the progression of chronic kidney disease: a possibility of a direct action of erythropoietin.
Tsuruya K; Yoshida H; Suehiro T; Fujisaki K; Masutani K; Kitazono T
Ren Fail; 2016; 38(3):390-6. PubMed ID: 26822074
[TBL] [Abstract][Full Text] [Related]
5. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
6. The Use of Erythropoiesis-Stimulating Agents in Patients With CKD and Cancer: A Clinical Approach.
Thavarajah S; Choi MJ
Am J Kidney Dis; 2019 Nov; 74(5):667-674. PubMed ID: 31395400
[TBL] [Abstract][Full Text] [Related]
7. In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study.
Ingrasciotta Y; Lacava V; Marcianò I; Giorgianni F; Tripepi G; D' Arrigo G; Chinellato A; Ugo Tari D; Santoro D; Trifirò G
BMC Nephrol; 2019 Sep; 20(1):359. PubMed ID: 31521117
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease.
Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Tonelli M; Garg AX; Pellegrini F; Ravani P; Jardine M; Perkovic V; Graziano G; McGee R; Nicolucci A; Tognoni G; Strippoli GF
Ann Intern Med; 2010 Jul; 153(1):23-33. PubMed ID: 20439566
[TBL] [Abstract][Full Text] [Related]
9. What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level?
Singh AK
Curr Opin Nephrol Hypertens; 2010 Sep; 19(5):420-4. PubMed ID: 20689425
[TBL] [Abstract][Full Text] [Related]
10. Factors related to the absence of anemia in hemodialysis patients.
Verdalles U; Abad S; Vega A; Ruiz Caro C; Ampuero J; Jofre R; Lopez-Gomez JM
Blood Purif; 2011; 32(1):69-74. PubMed ID: 21346339
[TBL] [Abstract][Full Text] [Related]
11. Postdialysis outcomes associated with consistent anemia treatment in predialysis patients with chronic kidney disease.
Wish JB; Nassar GM; Schulman K; del Aguila M; Provenzano R
Clin Nephrol; 2008 Apr; 69(4):251-9. PubMed ID: 18397699
[TBL] [Abstract][Full Text] [Related]
12. Anemia trials in CKD and clinical practice: refining the approach to erythropoiesis-stimulating agents.
de Francisco ALM; Piñera C
Contrib Nephrol; 2011; 171():248-254. PubMed ID: 21625120
[TBL] [Abstract][Full Text] [Related]
13. The effects of erythropoiesis stimulating therapy for anemia in chronic heart failure: A meta-analysis of randomized clinical trials.
Kang J; Park J; Lee JM; Park JJ; Choi DJ
Int J Cardiol; 2016 Sep; 218():12-22. PubMed ID: 27209352
[TBL] [Abstract][Full Text] [Related]
14. Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease.
Seliger SL; Zhang AD; Weir MR; Walker L; Hsu VD; Parsa A; Diamantidis CJ; Fink JC
Kidney Int; 2011 Aug; 80(3):288-94. PubMed ID: 21389972
[TBL] [Abstract][Full Text] [Related]
15. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S
Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375
[TBL] [Abstract][Full Text] [Related]
16. Erythropoiesis-stimulating agents in chronic kidney disease: what have we learned in 25 years?
Hung SC; Lin YP; Tarng DC
J Formos Med Assoc; 2014 Jan; 113(1):3-10. PubMed ID: 24090633
[TBL] [Abstract][Full Text] [Related]
17. Role of Erythropoiesis-Stimulating Agents in Cardiovascular Protection in CKD Patients: Reappraisal of Their Impact and Mechanisms.
Miura T; Sato T; Yano T; Takaguri A; Miki T; Tohse N; Nishizawa K
Cardiovasc Drugs Ther; 2023 Dec; 37(6):1175-1192. PubMed ID: 35150385
[TBL] [Abstract][Full Text] [Related]
18. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.
Carrero JJ; Bárány P; Yilmaz MI; Qureshi AR; Sonmez A; Heimbürger O; Ozgurtas T; Yenicesu M; Lindholm B; Stenvinkel P
Nephrol Dial Transplant; 2012 Feb; 27(2):709-15. PubMed ID: 21617198
[TBL] [Abstract][Full Text] [Related]
19. Timing of erythropoiesis-stimulating agent initiation and adverse outcomes in nondialysis CKD: a propensity-matched observational study.
Seliger S; Fox KM; Gandra SR; Bradbury B; Hsu VD; Walker L; Chiou CF; Fink JC
Clin J Am Soc Nephrol; 2010 May; 5(5):882-8. PubMed ID: 20299377
[TBL] [Abstract][Full Text] [Related]
20. [Regarding the optimal hemoglobin target range in renal anemia].
Maurin N
Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
